The Mamma HiToP Study - Trial NCT06132776
Access comprehensive clinical trial information for NCT06132776 through Pure Global AI's free database. This phase not specified trial is sponsored by Vienna Hospital Association and is currently Recruiting. The study focuses on Chemotherapy-induced Peripheral Neuropathy. Target enrollment is 160 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Vienna Hospital Association
Timeline & Enrollment
N/A
Nov 03, 2023
Dec 31, 2024
Primary Outcome
Alleviation of paresthesias (VAS)
Summary
The HiToP ® 191 PNP an certified device licensed for the treatment of neuropathia.
 
 The home-based treatment is to be performed only in accordance with the approved
 Investigational Plan (CIP) on subjects who have signed an informed consent form. Device use
 is limited to the approved study investigators.
 
 The study is multicenter, randomized, double-blind, and placebo-controlled.
 
 Primary Objective: Comparison of the change of paresthesias from baseline until end of
 therapy between the two patient groups, assessed by questionnaires
 
 Secondary Objectives: Further symptoms of neuropathy as well as on health-related quality of
 life.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06132776
Device Trial